Menu
Search
|

Menu

Close
X

Agios Pharmaceuticals Inc AGIO.OQ (NASDAQ Stock Exchange Global Select Market)

77.70 USD
-1.09 (-1.38%)
As of Feb 17
chart
Previous Close 78.79
Open 78.21
Volume 148,032
3m Avg Volume 194,928
Today’s High 79.06
Today’s Low 76.96
52 Week High 82.93
52 Week Low 45.20
Shares Outstanding (mil) 48.39
Market Capitalization (mil) 3,409.16
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY17
43
FY16
70
FY15
59
EPS (USD)
FY17
-6.743
FY16
-5.058
FY15
-3.140
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
63.74
5.77
Price to Book (MRQ)
vs sector
6.69
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-46.41
14.43
Return on Equity (TTM)
vs sector
-67.30
16.13

EXECUTIVE LEADERSHIP

David Schenkein
President, Chief Executive Officer, Director, Since 2013
Salary: $568,000.00
Bonus: --
Andrew Hirsch
Chief Financial Officer, Since 2016
Salary: $126,667.00
Bonus: --
Scott Biller
Chief Scientific Officer, Since 2010
Salary: $416,890.00
Bonus: --
Christopher Bowden
Chief Medical Officer, Since 2014
Salary: $436,091.00
Bonus: --
Steven Hoerter
Chief Commercial Officer, Since 2016
Salary: $363,125.00
Bonus: $375,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

88 Sidney St
CAMBRIDGE   MA   02139-4137

Phone: +1617.6498600

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.

SPONSORED STORIES